Wall Street analyst estimates for AEON Biopharma, Inc. (AEON): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.07 | ||
| 2026-08-12 | $-0.02 | $-0.23 | +91.1% |
| 2026-05-14 | $-0.44 | $-0.44 | +0.0% |
| 2026-03-30 | $-5.24 | $-0.17 | -2982.4% |
| 2025-11-14 | $-0.39 | $-0.43 | +9.3% |
| 2025-08-11 | $-0.60 | $-11.51 | +94.8% |
| 2025-05-14 | $2.28 | $-13.67 | +116.7% |
| 2025-03-24 | $3.75 | $-12.95 | +129.0% |
Valuation Ratios
| Price / Book | -0.85 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $2.5M | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $3.4M | $2.5M | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $4.8M | $7.3M | $25.7M | $34.8M | $33.0M | $14.2M | $4.1M |
| Selling, General & Admin | $46.0M | $11.6M | $11.2M | $13.7M | $19.8M | $13.6M | $12.2M |
| Operating Expenses | $57.3M | $18.9M | $65.8M | $48.4M | $348.1M | -$73.0M | $12.8M |
| Operating Income | -$54.0M | -$16.4M | -$65.8M | -$48.4M | -$348.1M | $73.0M | -$12.8M |
| EBITDA | -$47.5M | -$15.5M | -$36.9M | -$52.5M | -$52.7M | -$27.7M | -$16.2M |
| Interest Expense | $7.5M | $15000 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | $145.7M | -$32.9M | -$55.6M | -$52.6M | -$384.6M | $42.0M | -$39.2M |
| Income Tax | $14.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $172.9M | -$32.9M | -$55.6M | -$52.6M | -$384.6M | $42.0M | -$39.2M |
| EPS | $1481.04 | $-0.01 | $18.86 | $-27.25 | $-744.83 | $77.74 | $-3.95 |
| EPS (Diluted) | $1481.04 | $-0.01 | $18.86 | $-27.25 | $-744.83 | $72.93 | $-3.95 |
| Shares Outstanding (Diluted) | $92301 | $479166 | $434805 | $1.9M | $516399 | $575940 | $9.9M |
Price
| Price | $0.26 |
| Market Cap | $11M |
| Exchange | AMEX |
| Country | US |
Related companies: ABP · APM · BOLT · CING · CLNN · CLRB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of AEON: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks